Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
ustekinumab interleukin-12 alpha NA Successful target TTD , DGIDB Disease Management[MeSHID:D019468]
Necrosis[MeSHID:D009336]
Psoriasis[MeSHID:D011565]
Crohn Disease[MeSHID:D003424]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Arthritis
Psoriatic[MeSHID:D015535]
Ulcerative Colitis[MeSHID:D003093]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Inflammatory Bowel Diseases[MeSHID:D015212]
Malaria[MeSHID:D008288]		 6.37 approved inhibitor
ustekinumab interleukin-12 alpha NA Successful target TTD , DGIDB Disease Management[MeSHID:D019468]
Necrosis[MeSHID:D009336]
Psoriasis[MeSHID:D011565]
Crohn Disease[MeSHID:D003424]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Arthritis
Psoriatic[MeSHID:D015535]
Ulcerative Colitis[MeSHID:D003093]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Inflammatory Bowel Diseases[MeSHID:D015212]
Malaria[MeSHID:D008288]		 6.37 approved unknown
ustekinumab interleukin-23 biotech NA drugbank , DGIDB Disease Management[MeSHID:D019468]
Necrosis[MeSHID:D009336]
Psoriasis[MeSHID:D011565]
Crohn Disease[MeSHID:D003424]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Arthritis
Psoriatic[MeSHID:D015535]
Ulcerative Colitis[MeSHID:D003093]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Inflammatory Bowel Diseases[MeSHID:D015212]
Malaria[MeSHID:D008288]		 12.73 approved,investigational inhibitor
ustekinumab interleukin-12 subunit beta biotech NA drugbank , DGIDB Disease Management[MeSHID:D019468]
Necrosis[MeSHID:D009336]
Psoriasis[MeSHID:D011565]
Crohn Disease[MeSHID:D003424]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Arthritis
Psoriatic[MeSHID:D015535]
Ulcerative Colitis[MeSHID:D003093]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Inflammatory Bowel Diseases[MeSHID:D015212]
Malaria[MeSHID:D008288]		 12.73 approved,investigational inhibitor
ustekinumab interleukin-23 biotech Successful target TTD , drugbank , DGIDB Disease Management[MeSHID:D019468]
Necrosis[MeSHID:D009336]
Psoriasis[MeSHID:D011565]
Crohn Disease[MeSHID:D003424]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Arthritis
Psoriatic[MeSHID:D015535]
Ulcerative Colitis[MeSHID:D003093]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Inflammatory Bowel Diseases[MeSHID:D015212]
Malaria[MeSHID:D008288]		 6.37 approved,investigational inhibitor
ustekinumab polypeptide deformylase NA Successful target TTD , DGIDB Disease Management[MeSHID:D019468]
Necrosis[MeSHID:D009336]
Psoriasis[MeSHID:D011565]
Crohn Disease[MeSHID:D003424]
Dental Plaque[MeSHID:D003773]
Senile Plaques[MeSHID:D058225]
Arthritis
Psoriatic[MeSHID:D015535]
Ulcerative Colitis[MeSHID:D003093]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Inflammatory Bowel Diseases[MeSHID:D015212]
Malaria[MeSHID:D008288]		 0.91 approved unknown
click here to return to the previous page